Engineered Transcription Factors for Selective SCN1A Upregulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy approaches for treating genetic disorders in the central nervous system face challenges such as unwanted immune responses, off-target effects, and limited therapeutic duration, with a need for compositions and methods that can modulate gene expression with reduced immunogenicity and increased specificity for target genes.
Innovation Solution
Development of non-naturally occurring transcription factors with specific DNA binding domains and activating domains, linked in certain configurations, to enhance expression of the SCN1A gene, utilizing viral vectors like AAV9 for targeted gene delivery to parvalbumin neurons, and incorporating microRNA binding sites for selective expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional gene therapy approaches are used to treat genetic disorders in the central nervous system, then therapeutic delivery of nucleic acid can be achieved, but unwanted immune responses are elicited
Solution Approach 1:
The patent uses adeno-associated virus (AAV) vectors as intermediary carriers to deliver therapeutic nucleic acids to target cells in the central nervous system. AAV vectors are engineered to express specific transcription factors that modulate endogenous gene expression, providing therapeutic effect while eliciting reduced immune responses compared to traditional gene therapy approaches
Solution Approach 2:
The patent modifies the parameters of the therapeutic approach by using specific AAV serotypes (e.g., AAV9) with different tissue tropism characteristics and by engineering transcription factors with specific DNA binding domains and activating domains to achieve targeted gene regulation with improved safety profiles
2Reliability
If gene therapy is used to treat genetic disorders, then therapeutic effect can be achieved, but off-target effects occur
Solution Approach 1:
The patent employs transcription factors with specific DNA binding domains (such as zinc finger domains or TALE domains) that are designed to recognize and bind to specific target gene sequences. This specificity ensures that therapeutic effects are localized to the intended target genes (e.g., SCN1A) while minimizing off-target effects on other genes
Solution Approach 2:
The patent replaces traditional mechanical gene delivery methods with engineered transcription factors that use molecular recognition mechanisms (DNA-protein binding) to achieve targeted gene regulation, thereby improving specificity and reducing off-target effects
3Reliability
If gene therapy vehicles are used for therapeutic delivery, then gene delivery can be achieved, but cloning capacity is limited
Solution Approach 1:
The patent segments the therapeutic approach into separate functional components: the AAV vector delivers a minimal promoter and transcription factor expression cassette, while the target gene (SCN1A) remains in its endogenous genomic location. This segmentation allows the vector to remain within size limits while still achieving effective therapeutic delivery
4Reliability
If gene therapy is used to treat CNS diseases, then therapeutic intervention can be achieved, but sustaining therapeutic effect over longer period is challenging
Solution Approach 1:
The patent uses AAV vectors to deliver transcription factors that continuously regulate endogenous gene expression (e.g., SCN1A) over extended periods. The engineered transcription factors sustain therapeutic effects by maintaining appropriate expression levels of target genes, providing long-lasting benefit in treating CNS disorders like Dravet syndrome
Data Source
AI summary
Provided herein are engineered transcription factors for selective upregulation of SCN1a and uses thereof for treating diseases and disorders, such as, Dravet syndrome. Also provided are microRNA binding sites and uses thereof for selective expression in parvalbumin neurons.